TransMedics Group Inc TMDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
-
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
TransMedics to Present at the William Blair 46th Annual Growth Stock Conference
-
TransMedics Reports First Quarter 2026 Financial Results
-
TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH
-
The Quiet Rule Change Tilting $10B Toward Medtech's Most Validated Platforms
-
TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting
-
TransMedics Group Shares Rise on FDA Approval for Clinical Trial
Trading Information
- Previous Close Price
- $73.47
- Day Range
- $72.76–75.22
- 52-Week Range
- $60.12–155.91
- Bid/Ask
- $74.62 / $74.74
- Shares Outstanding
- 34.56M
- Market Cap
- $2.59B
- Volume/Avg
- 289,718 / 1M
Key Statistics
- Price/Earnings (Normalized)
- 17.01
- Price/Sales
- 4.61
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 898
- Website
- https://www.transmedics.com
Valuation
|
Metric
|
TMDX
|
|---|---|
Price/Earnings (Normalized) | 17.01 |
Price/Book Value | 5.17 |
Price/Sales | 4.61 |
Price/Cash Flow | 17.36 |
Price/Earnings
TMDX
Financial Strength
|
Metric
|
TMDX
|
|---|---|
Quick Ratio | 6.01 |
Current Ratio | 6.74 |
Interest Coverage | 6.24 |
Quick Ratio
TMDX
Profitability
|
Metric
|
TMDX
|
|---|---|
Return on Assets (Normalized) | 19.45% |
Return on Equity (Normalized) | 52.81% |
Return on Invested Capital (Normalized) | 22.39% |
Return on Assets
TMDX
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|@bvkF#^ | LOCK|!P?Jy | $175B | |||
| Stryker Corp
SYK
| LOCK|rt&gMM!p | LOCK|RB | $123B | |||
| Medtronic PLC
MDT
| LOCK|@^<j>! | LOCK|%Nfp | $106B | |||
| Boston Scientific Corp
BSX
| LOCK|D>n&<n | LOCK|zxtZP | $65B | |||
| Edwards Lifesciences Corp
EW
| LOCK|%>lx?K@ | LOCK|NJ?c | $49B | |||
| DexCom Inc
DXCM
| LOCK|w&@?%Pk | LOCK|Ly&K# | $30B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|%&^@>Xf | LOCK|X& | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|Kb | LOCK|h>S | $26B | |||
| Steris PLC
STE
| LOCK|>Vnsh!D | LOCK|$>&b! | $21B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|^Y!z<BYX | LOCK|#M | $18B |
United States